Peringkat dalam Saham
#42432
Based in France, Pharnext SA is a clinical-stage biopharmaceutical firm... Based in France, Pharnext SA is a clinical-stage biopharmaceutical firm dedicated to creating treatments for a range of neurodegenerative disorders, encompassing both rare (orphan) and common forms. Its pipeline features SYNGILITY, which has advanced through Phase III trials for Charcot-Marie-Tooth disease type 1A (CMT1A). Additionally, PXT864 has concluded Phase II clinical studies for Alzheimer's disease, and is also being explored for its potential in Parkinson's disease and amyotrophic lateral sclerosis (ALS). Pharnext also innovates with PLEOTHERAPY, a proprietary platform that harnesses big genetic data and artificial intelligence. In a collaborative effort, the company holds an agreement with the University Hospital Institute Mediterranee Infection to assess existing pharmaceuticals for their potential application against the COVID-19 virus. The organization was established in 2007, with its main offices located in Issy-Les-Moulineaux, France.
Harga Saham
$0.00023723
Terakhir disinkronkan: 2024-08-26
Kapitalisasi Pasar
$1.41K
Perubahan (1 hari)
111.67%
Perubahan (1 tahun)
0.00%
Perdagangan Pharnext S.A. (ALPHA)
Harga ALPHA dengan kapitalisasi pasar B
Kapitalisasi pasar dari Pharnext S.A.(ALPHA)
Kapitalisasi Pasar: $1.41K
Per August 2026, Pharnext S.A. memiliki kapitalisasi pasar sebesar $1.41K. Ini menjadikan Pharnext S.A. sebagai perusahaan 42432nd paling bernilai di dunia menurut data kami. Kapitalisasi pasar adalah nilai total saham beredar dari perusahaan publik dan biasanya digunakan untuk mengukur seberapa besar nilai sebuah perusahaan.
Riwayat kapitalisasi pasar Pharnext S.A. dari 2023 hingga 2026
ALPHA dibandingkan dengan 5 teratas stocks paling populer
| Harga ALPHA |
|
Aset B |
Pasar B |
Hasil |
|
|
|
|
$5.383T
|
+381,386,208,190.46%
|
|
|
|
|
$4.423T
|
+313,376,881,290.53%
|
|
|
|
|
$4.160T
|
+294,742,998,578.29%
|
|
|
|
|
$3.663T
|
+259,529,398,625.10%
|
|
|
|
|
$2.891T
|
+204,830,235,698.11%
|
